LifeMD CFO Vesting: 87,000 Shares Vested, Ownership Now 426,554

LifeMD, Inc. reporting person Marc David Benathen, the company's Chief Financial Officer, had 87,000 shares of common stock become vested and were reported as acquired on 08/22/2025 at a reported price of $0, described as performance stock that vested.

Rhea-AI Filing Summary

LifeMD, Inc. reporting person Marc David Benathen, the company's Chief Financial Officer, had 87,000 shares of common stock become vested and were reported as acquired on 08/22/2025 at a reported price of $0, described as performance stock that vested. Following the transaction he beneficially owns 426,554 shares. The Form 4 is filed individually by the reporting person and lists the reporting person's address as LifeMD, Inc., 236 Fifth Avenue, Suite 400, New York, NY 10001.

Positive

• 87,000 performance shares vested, increasing the CFO's direct ownership to 426,554 shares
• Clear disclosure of the compensatory nature of the acquisition (performance stock vested) consistent with Section 16 reporting

Negative

• None.

Insights

Financial Analyst

TL;DR: CFO received 87,000 vested performance shares, raising his stake to 426,554 shares; transaction appears compensatory, not a market purchase.

The reported acquisition reflects the vesting of performance-based equity rather than an open-market purchase, indicated by a $0 price and the explanatory note. Vesting increases the CFO's direct alignment with shareholders by increasing his stake, but does not alter company cash flows. For investors, this is a routine equity compensation event; absent other disclosures, it is unlikely to be material to valuation by itself.

Corporate Governance Expert

TL;DR: Grant vesting reported correctly; increases insider ownership and aligns incentives but raises no governance red flags.

The Form 4 clearly discloses an equity award vesting on 08/22/2025. The $0 price and explanatory note identify this as compensation-related. This disclosure meets Section 16 requirements and enhances transparency about executive ownership. No indications of derivative exercises, secondary sales, or atypical timing are present in the filing.

Insider Trade Summary

Grant/Award: 87,000 shares

Grant/Award 1 txn

Insider Benathen Marc David

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	87,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 426,554 shares (Direct)

Footnotes (1)

1. F1. Represents grant of performance stock which vested on August 22, 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LifeMD (LFMD) reporting person Marc David Benathen report on Form 4?

The Form 4 reports that CFO Marc David Benathen had 87,000 common shares acquired due to vesting of performance stock on 08/22/2025, at a reported price of $0.

How many shares does the CFO beneficially own after the reported transaction?

After the transaction the reporting person beneficially owns 426,554 shares of common stock.

Was the reported acquisition an open-market purchase or compensation-related?

The filing shows a $0 price and an explanation that the transaction "represents grant of performance stock which vested," indicating it was compensation-related.

When was the Form 4 filed and who signed it?

The signature block shows the reporting person signed the form on 08/26/2025 as Marc David Benathen.

Is this Form 4 a joint filing or filed by one reporting person?

The form is marked as filed by one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/26/2025 - 06:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Benathen Marc David

(Last) (First) (Middle)

C/O LIFEMD, INC.

236 FIFTH AVENUE, SUITE 400

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		A		87,000	A	$0(1)	426,554	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of performance stock which vested on August 22, 2025

	/s/ Marc David Benathen	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.